Abstract


Bookmark and Share

HbA1c and coronary heart disease risk among diabetic patients

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G
Diabetes Care 2014 ;37:428-35


OBJECTIVE: Clinical trials to date have not provided definitive evidence regarding the effects of glucose lowering with coronary heart disease (CHD) risk among diabetic patients.
RESEARCH DESIGN AND METHODS: We prospectively investigated the association of HbA1c at baseline and during follow-up with CHD risk among 17,510 African American and 12,592 white patients with type 2 diabetes.
RESULTS: During a mean follow-up of 6.0 years, 7,258 incident CHD cases were identified. The multivariable-adjusted hazard ratios of CHD associated with different levels of HbA1c at baseline (<6.0 [reference group], 6.0-6.9, 7.0-7.9, 8.0-8.9, 9.0-9.9, 10.0-10.9, and =11.0%) were 1.00, 1.07 (95% CI 0.97-1.18), 1.16 (1.04-1.31), 1.15 (1.01-1.32), 1.26 (1.09-1.45), 1.27 (1.09-1.48), and 1.24 (1.10-1.40) (P trend = 0.002) for African Americans and 1.00, 1.04 (0.94-1.14), 1.15 (1.03-1.28), 1.29 (1.13-1.46), 1.41 (1.22-1.62), 1.34 (1.14-1.57), and 1.44 (1.26-1.65) (P trend <0.001) for white patients, respectively. The graded association of HbA1c during follow-up with CHD risk was observed among both African American and white diabetic patients (all P trend <0.001). Each one percentage increase of HbA1c was associated with a greater increase in CHD risk in white versus African American diabetic patients. When stratified by sex, age, smoking status, use of glucose-lowering agents, and income, this graded association of HbA1c with CHD was still present.
CONCLUSIONS: The current study in a low-income population suggests a graded positive association between HbA1c at baseline and during follow-up with the risk of CHD among both African American and white diabetic patients with low socioeconomic status.

 

Diabetes Care 2014 ;37:428-35

 

 


Area Soci

Eventi

38° Congresso Nazionale


38° Congresso Nazionale

Bologna, 1-3 dicembre 2024

[continua a leggere]

Congresso Regionale SISA Sezione Campania

Napoli, 13 Dicembre 2023

[continua a leggere]

Congresso Regionale SISA Sezione Siculo-Calabra

Catania, 3-4 Dicembre 2023

[continua a leggere]

SISA LIPID ACADEMY - Corso avanzato di lipidologia clinica

Modena, 22-23 Giugno 2023

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 14 • N.4/2023

[continua a leggere]

HoFH today

Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 5 • N.1/2023

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2018: 3.340


Diateca

EAS Lipid Clinic Webinar - Le linee guida per le dislipidemie: presente e futuro
[continua a leggere]
EAS Advanced Course in Rare Lipid Disease
[continua a leggere]

Newsletter

Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

LIPIGEN
Nuovo sito dedicato al Progetto LIPIGEN

 

Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA

 

PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti